Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600129036) titled 'Intralesional Bevacizumab Injection for the Treatment of Recurrent Respiratory Papillomatosis' on July 29.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The Affiliated BenQ Hospital of Nanjing Medical University

Condition: Recurrent Respiratory Papillomatosis

Recruitment Status: Recruiting

Phase: N/A

Date of First Enrollment: 2025-12-28

Target Sample Size: Test group:15;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=302038

Published by HT Digital Content Services with permission from Health Daily Digest....